復旦張江(688505.SH)：擬總計2.665億元取得上海漢都39.5663%的股權
格隆匯 3 月 25日丨復旦張江(688505.SH)公佈，公司擬以人民幣10242萬元，認購上海漢都醫藥科技有限公司(“上海漢都”或“目標公司”)發行的138.0526萬美元新增註冊資本；同時，公司擬與上海漢都現有股東Hong Kong WD Pharmaceutical Co., Limited (“香港漢都”)等主體簽訂《股權轉讓協議》，約定公司擬以2524.3137萬美元(預計折合人民幣約16408萬元，因匯率變動，實際支付的人民幣金額將根據相關協議安排以付款日期當日匯率為準)受讓香港漢都持有的上海漢都276.5490萬美元註冊資本所對應的股權。
此次交易全部完成後，公司合計持有上海漢都414.6016萬美元註冊資本，對應39.5663%的股權，預計公司出資總額約為人民幣26650萬元(因匯率變動，實際支付的人民幣金額將根據相關協議安排以付款日期當日匯率為準)。
上海漢都是一家由美國資深創業團隊創立的創新藥研發公司，公司致力於開發滿足臨牀剛需的、具有國際領先、自主知識產權以及全球專利的藥械合一的新藥產品，以美國、歐洲及國內快速同步申報為基本策略，同時開發高價值高端特殊製劑產業化平台。截至目前，在研項目以5個技術平台為依託，聚焦具有高技術壁壘的505(b)(2)核心產品，精耕神經系統、心血管系統和免疫系統領域。
505(b)(2)和仿製藥相比較於創新藥，研發成功的概率較高，公司的經營風險低於創新藥研發企業，其選擇的管線品種針對的適應症帕金森，具有巨大的未滿足的臨牀需求，而該領域新靶點新分子實體藥物獲批難度很大，505(b)(2)途徑申報項目是獲得新品種參與市場競爭的優選方式之一。
目標公司主導的在研項目在國內相關領域內具有先發優勢。目標公司目前處於虧損狀態，因其研發項目尚在研究開發階段，尚未進入商業化生產。公司看重其研發潛力及在研項目價值，相信此次收購及此次增資將擴展公司在研產品的臨牀應用領域，進一步加快在研新藥研發進程，推動在研產品的儘快上市。此次收購及此次增資順應行業發展趨勢，符合公司發展戰略，有利於拓展公司業務領域，豐富產品管線；通過加強產品及學術推廣，有利於提升公司未來新藥市場競爭能力和公司品牌知名度，從而提升公司長期盈利能力及綜合競爭力，實現公司的長期可持續發展，維護股東的長遠利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
